Options for reducing oxidative toxicity of l-dopa by combination with synthetic or natural radical protectors

Abstract

Parkinson disease (PD) is a multifactorial disease that is not well-established. It takes a leading place among contemporary frequent diseases of the central nervous system (CNS). The levodopa (L-dopa) clinical effect is diminished by motor complications resulting from prolonged treatment. Due to the L-dopa neurotoxic effect in the disease treatment, the L-dopa administration is delayed as long as possible in order to avoid side effects. In addition, combining L-dopa therapy with antioxidants (from natural or synthetic origin), may decrease side-effects and provide symptomatic relief. The aim of the current research is through experimental model of healthy mice to explore the possibility to reduce the oxidative stress (OS) induced by the L-dopa drug after its combining with: an essential oil isolated from Rosa damascena Mill., the vitamin C and synthetic antioxidant 1-ethyl-3- [4- (2,2,6,6-tetramethylpiperidine-1-oxyl)] - 1-nitrosourea SLENU. The antioxidants protective effects against the L-dopa oxidative toxicity were evaluated through the oxidative stress indicators - the lipid and protein oxidation end products – measured as MDA, protein carbonyl content, and advanced glycation end products (AGEs) in blood plasma of experimental mice.

Keywords

• Parkinson disease
• L-dopa
• natural antioxidants
• synthetic antioxidants
• PCC
• AGEs